Technology Offer

CIBERER is making available its technologyl range of patents to be exploited:

• OT - Bioengineered Skin for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
  
• New Therapy for the treatment of epidermolysis bullosa
  
• Ex vivo gene therapy approach in Diamond Blackfan Anemia (DBA)
• In vivo lentiviral gene therapy for the treatment of Primary Hyperoxaluria Type-1
• Predictive models and artificial intelligence tools for the early diagnosis of sepsis and clinical evolution for sepsis and septic shock patients
• Quinolylnitrone derivates for use in the prevention and treatment of hearing loss.
• Crispr EHCas9 molecular biology tool
  
• Applicative for mobile phone (App) for McArdle and other rare glucogenosis.
  
• Gene Therapy for Glutaric Aciduria
• Compounds for the use in the treatment of anemias
  
• Compositions for use in a method of providing improved hematopoietic stem cell engraftment
• Allopurinol: a potential new pharmacological treatment against aortic aneurysm in Marfan syndrome
• Gene editing strategy for the treatment of dystrophic epidermolysis bullosa
• Functional in house Assays for Immunodeficiencies in Lymphocytes by Cytometry

Here we will publish CIBERINFEC-technology-offer information when available